Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: Evaluation of radiological and pathological response

Journal of Surgical Oncology

Volumn 105, Issue 7, 2012, Pages 692-698

  Facciuto, Marcelo E ^a   Singh, Manoj K ^a   Rochon, Caroline ^b   Sharma, Jyoti ^b   Gimenez, Cecilia ^b   Katta, Umadevi ^b   Moorthy, Chitti R ^b   Bentley Hibbert, Stuart ^b   Rodriguez Davalos, Manuel ^c   Wolf, David C ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c Yale New Haven Transplantation Center   (United States)

Author keywords

Hepatocellular carcinoma; pathological response; radiological response; SBRT

Indexed keywords

ADULT; ARTICLE; BRAIN HEMORRHAGE; CANCER CONTROL; CANCER RECURRENCE; CLINICAL ARTICLE; DISEASE COURSE; END STAGE LIVER DISEASE; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; OVERALL SURVIVAL; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION SICKNESS; SEPSIS; STEREOTACTIC BODY RADIATION THERAPY; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR NECROSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RADIOSURGERY;

EID: 84859920492     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22104     Document Type: Article

References (60)

1. Ries LAG, Melbert D, Krapcho M, et al.: SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, based on November 2007 SEER data submission, posted to SEER web site, 2008. Available from:.
2. El-Serag HB,: Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology 2004; 127: S27-S34. (Pubitemid 39423367)
3. Sha SA, Cleary SP, Tan JCC, et al.: An analysis of resection vs transplantation for early hepatocellular carcinoma: Defining the optimal therapy at a single institution. Ann Surg Oncol 14: 2608-2614.
4. Llovet JM, Mas X, Aponte JJ, et al.: Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002; 50: 123-128. (Pubitemid 34028315)
5. Roayaie S, Frischer JS, Emre SH, et al.: Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002; 235: 533-539. (Pubitemid 34258353)
6. Llovet JM, Fuster J, Bruix J,: Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology 1999; 30: 1434-1440.
7. Porrett PM, Peterman H, Rosen M, et al.: Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl 2006; 12: 665-673.
8. Kennedy AS, Nutting C, Coldwell D, et al.: Pathological response and microdosimetry of (90)Y microspheres in man: Review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004; 60: 1552-1563. (Pubitemid 39601873)
9. Sato K, Lewandowski RJ, Bui JT, et al.: Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere®): Assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006; 29: 522-529. (Pubitemid 43822993)
10. Salem R, Lewandowski RJ, Mulcahy MF, et al.: Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64.
11. Liu CY, Liao HF, Shih SC, et al.: Colchicine sensitized human hepatocellular carcinoma cells to damages caused by radiation. World J Gastroenterol 2005; 11: 4237-4240.
12. Geng CX, Zeng ZC, Wang JY, et al.: Docetaxel shows radiosensitization in human hepatocellular carcinoma cells. World J Gastroenterol 2005; 11: 2990-2993.
13. Munden RF, Erasmus JJ, Smythe WR, et al.: Radiation injury to the liver after intensity-modulated radiation therapy in patients with mesothelioma: An unusual CT appearance. Am J Radiol 2005; 184: 1091-1095. (Pubitemid 43821881)
14. Chung HT, Lee B, Park E, et al.: Can all centers plan intensity-modulated radiotherapy (IMRT) effectively? An external audit of dosimetric comparisons between three-dimensional conformal radiotherapy and IMRT for adjuvant chemoradiation for gastric cancer. Int J Radiat Oncol Biol Phys 2008; 71: 1167-1174.
15. Sternick E, editor. The theory practice of intensity modulated radiation therapy. Madison, WI: Advanced Medical Publishing; 1997.
16. Ogino H, Shibamoto Y, Sugie C, et al.: Biological effects of intermittent radiation in cultured tumor cells: Influence of fraction number and dose per fraction. J Radiat Res 2005; 46: 401-406. (Pubitemid 43268404)
17. Blomgren H, Lax I, Naslund I, et al.: Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of first thirty-one patients. Acta Oncol 1995; 34: 861-870.
18. Takeda A, Takahashi M, Kunieda E, et al.: Hypofractionated stereotactic radiotherapy with and without transarterial chemoembolization for small hepatocellular carcinoma not eligible for other ablation therapies: Preliminary results for efficacy and toxicity. Hepatol Res 2008; 38: 60-69. (Pubitemid 350182577)
19. Mendez Romero A, Wunderink W, Hussain SM, et al.: Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase I-II study. Acta Oncol 2006; 45: 831-837. (Pubitemid 44423129)
20. Tse RV, Hawkins M, Lockwood G, et al.: Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008; 26: 657-664. (Pubitemid 351264363)
21. Wulf J, Guckenberger M, Haedinger U, et al.: Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol 2006; 45: 838-847. (Pubitemid 44423130)
22. Herfarth KK, Debus J, Lohr F, et al.: Stereotactic single-dose radiation therapy of liver tumors: Result of a phase I/II trial. J Clin Oncol 2001; 19: 164-170. (Pubitemid 32063493)
23. Schefter TE, Kavanagh BD, Timmerman RD, et al.: A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 2005; 62: 1371-1378. (Pubitemid 40982057)
24. Kwon JH, Bae SH, Kim JY, et al.: Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 2010; 10: 475.
25. Seo YS, Kim MS, Yoo SY, et al.: Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol. 2010; 102: 209-214.
26. Edge SB, Byrd DR, Compton CC, et al., editors: AJCC cancer staging manual. 7th edition, Springer; 2010.
27. Kamath PS, Wiesner RH, Malinchoc M, et al.: A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470. (Pubitemid 32119037)
28. United Network for Organ Sharing. Liver Transplant Candidates with hepatocellular carcinoma (HCC) Policy 3.6.4.4. 2002.
29. Therasse P, Arbuck SG, Eisenhauer ES, et al.: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
30. Mazzaferro V, Regalia E, Doci R, et al.: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. NEJM 1996; 334: 693-699. (Pubitemid 26079803)
31. Yoo HY, Patt CH, Geschwind JF, et al.: The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1987 and 2001: 5-Year survival has improved significantly with time. J Clin Oncol 21: 4329-4335.
32. Schwartz M, Roayaie S, Uva P,: Treatment of HCC in patients awaiting liver transplantation. Am J Transplant 2007; 7: 1875-1881. (Pubitemid 47037976)
33. Liver Cancer Study Group of Japan. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 1994; 74: 2772-2780.
34. Bismuth H, Majno PE,: Hepatobiliary surgery. J Hepatol 2000; 32: 208-224. (Pubitemid 30123636)
35. Arii S, Yamaoka Y, Futagawa S, et al.: Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan. Hepatology 2000; 32: 1224-1229.
36. Lau WY, Leung TWT, Yu SCH, et al.: Percutaneous local ablative therapy for hepatocellular carcinoma. Ann Surg 2003; 237: 171-179.
37. Lencioni R, Cioni D, Bartolozzi C,: Percutaneous radiofrequency thermal ablation of liver malignancies: Techniques, indications, imaging findings, and clinical results. Abdom Imaging 2001; 26: 345-360. (Pubitemid 32565864)
38. Curly SA, Izzo F, Ellis LM, et al.: Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000; 232: 381-391.
39. Livraghi T, Goldberg SN, Lazzaroni S, Meloni, et al.: Small hepatocellular carcinoma: Treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210: 655-661. (Pubitemid 29124024)
40. Cho YK, Rhim H, Noh S,: Radiofrequency ablation versus surgical resection as primary treatment of hepatocellular carcinoma meeting the Milan criteria: A systematic review. J Gastroenterol Hepatol. DOI: 10.1111/j.1440-1746.2011.06812. x.
41. Huang J, Yan L, Cheng Z, et al.: A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010; 252: 903-912.
42. Lencioni RA, Allgaier HP, Cioni D, et al.: Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-240. (Pubitemid 36736097)
43. Lin SM, Lin CJ, Lin CC, et al.: Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma cm. Gastroenterology 2004; 127: 1714-1723.
44. Shiina S, Teratani T, Obi S, et al.: A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122-130. (Pubitemid 41002049)
45. Decadt B, Siriwardena AK,: Radiofrequency ablation of liver tumors: Systematic review. Lancet Oncol 2004; 5: 550-560. (Pubitemid 39194044)
46. Oldhafer KJ, Chavan A, Fruhauf NR, et al.: Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: Marked tumor necrosis, but no survival benefit? J Hepatol 1998; 29: 953-959. (Pubitemid 28559065)
47. Graziadei IW, Sandmueller H, Waldenberger P, et al.: Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003; 9: 557-563. (Pubitemid 36701690)
48. Maddala YK, Stadheim L, Andrews JC, et al.: Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: Outcome with chemoembolization. Liver Transpl 2004; 10: 449-455. (Pubitemid 38380323)
49. Yuen MF, Chan AO, Wong BC, et al.: Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: Results of a comparative study in 96 Chinese patients. Am J Gastroenterol. 2003; 98: 1181-1185. (Pubitemid 36733785)
50. Bargellini I, Sacco R, Bozzi E, et al.: Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: A prospective cohort study. Eur J Radiol 2011; [Epub ahead of print].
51. Malagari K, Chatzimichael K, Alexopoulou E, et al.: Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: Results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 2008; 31: 269-280.
52. Varela M, Real MI, Burrel M, et al.: Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-481. (Pubitemid 46201723)
53. Lammer J, Malagari K, Vogl T, et al.: On behalf of the PRECISION V Investigators Prospective Randomized Study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V Study. Cardiovasc Intervent Radiol 2010; 33: 41-52.
54. Nicolini A, Martinetti L, Crespi S, et al.: Transarterial chemoembolization with epirubicin-eluting beads versus transarterial chemoembolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21: 327-332.
55. Reyes DK, Vossen JA, Kamel IR, et al.: Single center phase-II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: Initial experience in the United States. Cancer J 2009; 15: 526-532.
56. Lewandowski RJ, Kulik LM, Riaz A, et al.: A comparative analysis of transarterial downstaging for hepatocellular carcinoma: Chemoembolization versus radioembolization. Am J Transplant 2009; 9: 1920-1928.
57. Park W, Lim DH, Paik SW, et al.: Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005; 61: 1143-1150. (Pubitemid 40340909)
58. Ben-Josef E, Normolle D, Ensminger WD, et al.: Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005; 23: 8739-8747. (Pubitemid 46211519)
59. Seong J,: Recent developments in radiotherapy of hepatocellular carcinoma. Korean J Hepatol 2004; 10: 241-247.
60. Kubas A, Mornex F, Merle P, et al.: Irradiation of hepatocellular carcinoma: Impact of breathing on motions and variations of volume of the tumor, liver and upper abdominal organs. Cancer Radiother 2008; 12: 768-774.